Show simple item record

dc.contributor.authorSemeere, Aggrey S.
dc.contributor.authorBusakhala, Naftali
dc.contributor.authorMartin, Jeffrey N.
dc.date.accessioned2013-01-04T12:26:20Z
dc.date.available2013-01-04T12:26:20Z
dc.date.issued2012
dc.identifier.citationSemeere, A.S., Busakhala, N., Martin, J.N. (2012). Impact of antiretroviral therapy on the incidence of Kaposi’s sarcoma in resource-rich and resource-limited settings. Current Opinion in Oncology, 24(5)en_US
dc.identifier.issn1040-8746
dc.identifier.uriDOI:10.1097/CCO.0b013e328355e14b
dc.identifier.urihttp://hdl.handle.net/10570/953
dc.description.abstractPurpose of review Given the recent availability of antiretroviral therapy (ART) in resource-limited settings and the significant burden exacted by Kaposi’s sarcoma in these areas, we reviewed data regarding the impact of ART on Kaposi’s sarcoma incidence. We summarized the sizeable literature in resource-rich settings as well as emerging data from resource-limited regions. Importantly, we delineated ways impact can be defined, including individual patient-level effectiveness; population-level effectiveness; change in population-level incidence; and residual risk of Kaposi’s sarcoma. Recent findings In resource-rich settings, there are now ample data demonstrating beneficial individual patient-level and population-level effects of ART on Kaposi’s sarcoma incidence. There is, however, considerable variability between studies and important methodologic shortcomings. Data from resource-limited settings are much more limited; although they preliminarily indicate individual patient-level effectiveness, they do not yet provide insight on population-level effects. Summary ART has had a substantial impact on Kaposi’s sarcoma incidence in resource-rich settings, but more attention is needed on validly quantifying this effect in order to determine whether additional interventions are needed. Emerging data from resource-limited regions also suggest beneficial impact of ART on Kaposi’s sarcoma incidence, but – given the scope of Kaposi’sen_US
dc.description.sponsorshipFunding: National Institutes of Health (R01 CA119903, D43 CA153717, U01 AI069911, and P30 AI027763). We thank Megan Wenger and Melissa Assenzio for assistance with literature review.en_US
dc.language.isoenen_US
dc.publisherLippincott, Williams & Wilkinsen_US
dc.subjectHIV/AIDSen_US
dc.subjectKaposi’s sarcomaen_US
dc.subjectAntiretroviral therapyen_US
dc.subjectARTen_US
dc.titleImpact of antiretroviral therapy on the incidence of Kaposi’s sarcoma in resource-rich and resource-limited settingsen_US
dc.typeJournal article, peer revieweden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record